Acorah Software Products - Accounts Production 15.0.600 false true 31 March 2023 1 April 2022 false 1 April 2023 31 March 2024 31 March 2024 11933728 Dr M Wiles Dr G Rutherford iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11933728 2023-03-31 11933728 2024-03-31 11933728 2023-04-01 2024-03-31 11933728 frs-core:CurrentFinancialInstruments 2024-03-31 11933728 frs-core:ComputerEquipment 2024-03-31 11933728 frs-core:ComputerEquipment 2023-04-01 2024-03-31 11933728 frs-core:ComputerEquipment 2023-03-31 11933728 frs-core:RevaluationReserve 2023-04-01 2024-03-31 11933728 frs-core:RevaluationReserve 2023-03-31 11933728 frs-core:RevaluationReserve 2024-03-31 11933728 frs-core:ShareCapital 2024-03-31 11933728 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31 11933728 frs-bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 11933728 frs-bus:FilletedAccounts 2023-04-01 2024-03-31 11933728 frs-bus:SmallEntities 2023-04-01 2024-03-31 11933728 frs-bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 11933728 frs-bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 11933728 frs-core:DeferredTaxation 2023-04-01 2024-03-31 11933728 frs-core:DeferredTaxation 2023-03-31 11933728 frs-core:DeferredTaxation 2024-03-31 11933728 frs-core:UnlistedNon-exchangeTraded 2024-03-31 11933728 frs-core:UnlistedNon-exchangeTraded 2023-03-31 11933728 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-03-31 11933728 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2024-03-31 11933728 frs-core:RevaluationsIncreaseDecreaseInInvestments frs-core:UnlistedNon-exchangeTraded 2024-03-31 11933728 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-03-31 11933728 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-03-31 11933728 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-03-31 11933728 frs-bus:Director1 2023-04-01 2024-03-31 11933728 frs-bus:Director2 2023-04-01 2024-03-31 11933728 frs-countries:EnglandWales 2023-04-01 2024-03-31 11933728 2022-03-31 11933728 2023-03-31 11933728 2022-04-01 2023-03-31 11933728 frs-core:CurrentFinancialInstruments 2023-03-31 11933728 frs-core:RevaluationReserve 2023-03-31 11933728 frs-core:ShareCapital 2023-03-31 11933728 frs-core:RetainedEarningsAccumulatedLosses 2023-03-31
Registered number: 11933728
Wiles-Rutherford Medical Ltd
Unaudited Financial Statements
For The Year Ended 31 March 2024
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—5
Page 1
Balance Sheet
Registered number: 11933728
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 807 1,346
Investments 5 126,368 74,082
127,175 75,428
CURRENT ASSETS
Debtors 6 16,285 15,928
Cash at bank and in hand 211,106 161,130
227,391 177,058
Creditors: Amounts Falling Due Within One Year 7 (29,769 ) (21,335 )
NET CURRENT ASSETS (LIABILITIES) 197,622 155,723
TOTAL ASSETS LESS CURRENT LIABILITIES 324,797 231,151
PROVISIONS FOR LIABILITIES
Deferred Taxation 8 (153 ) (256 )
NET ASSETS 324,644 230,895
CAPITAL AND RESERVES
Called up share capital 10 200 200
Revaluation reserve 11 6,000 (6,037 )
Profit and Loss Account 318,444 236,732
SHAREHOLDERS' FUNDS 324,644 230,895
Page 1
Page 2
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr M Wiles
Director
12/08/2024
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Wiles-Rutherford Medical Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11933728 . The registered office is 4 Holt House Grove, Sheffield, S7 2QG.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Computer Equipment 25% straight line
2.4. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences.

3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2023: NIL)
- -
4. Tangible Assets
Computer Equipment
£
Cost
As at 1 April 2023 2,155
As at 31 March 2024 2,155
Depreciation
As at 1 April 2023 809
Provided during the period 539
As at 31 March 2024 1,348
Net Book Value
As at 31 March 2024 807
As at 1 April 2023 1,346
Page 3
Page 4
5. Investments
Unlisted
£
Cost
As at 1 April 2023 74,082
Additions 40,249
Revaluations 12,037
As at 31 March 2024 126,368
Provision
As at 1 April 2023 -
As at 31 March 2024 -
Net Book Value
As at 31 March 2024 126,368
As at 1 April 2023 74,082
6. Debtors
2024 2023
£ £
Due within one year
Trade debtors 13,207 14,827
Prepayments and accrued income 3,078 1,101
16,285 15,928
7. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Corporation tax 25,159 18,457
Accruals and deferred income 1,064 1,653
Directors' loan accounts 3,546 1,225
29,769 21,335
8. Deferred Taxation
The provision for deferred tax is made up as follows:
2024 2023
£ £
Other timing differences 153 256
Page 4
Page 5
9. Provisions for Liabilities
Deferred Tax Total
£ £
As at 1 April 2023 256 256
Deferred taxation (103 ) (103 )
Balance at 31 March 2024 153 153
Provision is made for the potential charge to tax that would arise should the company dispose of its fixed assets at the stated net book value to the extent that this is in excess of the tax written down value.
10. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 200 200
11. Reserves
Revaluation Reserve
£
As at 1 April 2023 (6,037 )
Transfer to profit and loss 12,037
As at 31 March 2024 6,000
Page 5